Which companies depend on AstraZeneca as a customer?

Nektar Therapeutics reports AstraZeneca as 37% of its revenue. Share of each supplier's revenue: Nektar Therapeutics 37%.

AZNAstraZeneca PLC

Healthcare

$171.49+3.4% 1Y

$171.49

$155.6052 weeks$208.62

Is the business good?

Mixed

Margins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 neutral, 3 without data

Margin direction, 3 yearsStablederived

Margins have held roughly steady, a stable cost structure.

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

Customers and suppliers

Who buys from AZN and who it buys from, as the companies report it.

Customerswho buys

None disclosed.

Supplierswho it buys from

NKTRNektar Therapeutics
37%
AZN is 37% of its revenue · FY2025 10-K

A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; AZN’s own figures are from its FY2025 20-F. Smaller customers and suppliers go unreported.

Drug Manufacturers, General

Ranks #5 of 7 by RyuScore